Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer

Area of Science:

• Oncology
• Cancer Biology
• Pharmacology

Background:

• Triple negative breast cancer (TNBC) is an aggressive subtype lacking ER, PR, and HER2 targets.
• Conventional chemotherapy is the primary treatment but often leads to acquired drug resistance.
• Monotherapy is ineffective for high-grade tumors like TNBC due to inherent genetic instability.

Purpose of the Study:

• To explore novel combinatorial therapeutic strategies for TNBC.
• To identify combination therapies that improve treatment efficacy and overcome chemoresistance.
• To investigate targeted pathways including PARP, EGFR, PI3K, AR, wnt signaling, HDAC, and MEK.

Main Methods:

• Review of current literature on TNBC treatment strategies.
• Analysis of emerging combinatorial approaches targeting specific molecular pathways.
• Focus on therapies designed to circumvent or delay drug resistance.

Main Results:

• Combination therapies demonstrate superior or equivalent efficacy compared to monotherapy.
• Targeting multiple pathways simultaneously can enhance anti-tumor effects.
• Reduced dosages in combination regimens may lower toxicity and chemoresistance.

Conclusions:

• Novel combination therapies targeting pathways like PARP, EGFR, PI3K, AR, wnt, HDAC, and MEK are promising for TNBC.
• Combination strategies are crucial for overcoming chemoresistance and improving patient outcomes.
• Further research into these combinatorial approaches is warranted for efficient TNBC treatment.